JPRN-UMIN000004894已完成未知
Effect and Safety of dose-escalating treatment of Imidafenacin for Overactive Bladder : CLSS-modified-Self-Assessment Goal Achievement questionnaire - CLSS-modified-SAGE study
Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan0 个研究点目标入组 500 人开始时间: 2011年1月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Polyuria (daily urine volume >=3000mL) 2)Residual urine >=100mL 3)Suspect of prostate cancer 4)Indwelling catheter or self intermittent urinary catherization 5)The shift work and patients with irregular lifestyle 6)Bladder training conducted over the past 10 days 7)Active urinary tract infection 8)Having been given hormones or 5 alpha-reductase inhibitor within the past six months 9)Contraindication to imidafenacin (Primary angle-closure glaucoma , urinary retention , Obstructive intestinal disease, paralytic ileus, gastrointerstinal atony , myastania gravis ) 10)Judged as being unsuitable for the trial by the researcher.
研究者
相似试验
进行中（未招募）
不适用
first in man study with CetuGEX in patients with metastatic cancerHistologically confirmed locally advanced and/or metastatic solid organ tumourMedDRA version: 14.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019552-50-DEGlycotope GmbH85
已完成
不适用
Efficacy and safety of treatment with moderate doses of corticosteroid and immunosuppressants in rheumatoid arthritis patients with interstitial lung diseaseInterstitial lung disease related to rheumatoid arthritisJPRN-UMIN000010126Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University34
招募中
1 期
PHASE-I CLINICAL TRIAL OF INHALED FORMULATIONS OF LIFEVIROTREAT.CTRI/2021/04/033295Supreme Industries India
已完成
不适用
Evaluation of efficacy of dose escalation strategy for treatment with sorafenib for hepatocellular carcinoma.Hepatocellular carcinomaJPRN-UMIN000009126Kanazawa Medical University20
尚未招募
1 期
euroEPO – Type 2 Spinocerebellar Ataxia Phase I-IIType 2 Spinocerebellar AtaxiaRPCEC00000187Center of Molecular Immunology (CIM), CIMAB34